Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Hepatectomy Plus Adjuvant mFOLFOX6 Improves DFS in Liver-Only Metastatic CRC

January 6th 2022

Adjuvant chemotherapy with modified fluoropyrimidine, leucovorin, and oxaliplatin improved disease-free survival among patients with liver-only metastases from colorectal cancer who were treated with hepatectomy.

Anti-EGFR Treatment Grows in Prominence for CRC

January 4th 2022

With an influx of new trials examining the use of anti-EGFR treatments in patients with advanced colorectal cancer, attention must be paid to finding the optimal window in which to give these therapies to maximize benefit.

Dr. Jain on the Push Toward Personalized Treatment Approaches in CRC With Liver Metastases

January 3rd 2022

Shikha Jain, MD, FACP, discusses the push toward personalized treatment approaches in colorectal cancer with liver metastases.

Dr. Spaggiari on the Potential Utility of Liver Transplantation in CRC With Liver Metastases

December 23rd 2021

Mario Spaggiari, MD, discusses the potential utility of liver transplantation as a treatment option for patients with colorectal cancer liver metastases.

Dr. Bekaii-Saab on the Benefits Derived With Bevacizumab Plus TAS-102 in mCRC

December 22nd 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the addition of bevacizumab to trifluridine/tipiracil in patients with metastatic colorectal cancer

Dr. Jain on the Importance of Communication for Multidisciplinary Care in CRC

December 21st 2021

Shikha Jain, MD, FACP, discusses the importance of communication in patients with colorectal cancer and liver metastases who are receiving multidisciplinary care.

Dr. Shirasu on the Clinical Implications of ctDNA in CRC

December 20th 2021

Hiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.

Surgical Resectability Remains Crucial in Determining Treatment Strategy in Liver-Only Metastatic CRC

December 20th 2021

Early identification of patients with liver-only metastatic colorectal cancer who are eligible for resection is crucial to determining their course of treatment and what role modalities like chemotherapy will play in their treatment strategy.

Dr. Ciombor on the Utilization of Maintenance Panitumumab in RAS Wild-Type Metastatic CRC

December 20th 2021

Kristen K. Ciombor, MD, MSCI, discusses the use of panitumumab in the maintenance treatment of patients with RAS wild-type metastatic colorectal cancer.

Dr. Hubbard on the Design of the NRG-GI005 Trial in Colorectal Cancer

December 17th 2021

Joleen M. Hubbard, MD, discusses the design of the ongoing phase 2/3 NRG-GI005 trial in patients with stage IIA colorectal cancer after surgery.

Adavosertib Elicits Efficacy in RAS/TP53+ mCRC With Potential Additive Benefit in Left-Sided Tumors

December 16th 2021

The WEE1 inhibitor adavosertib improved progression-free survival with a tolerable safety profile compared with active monitoring in patients with RAS/TP53-mutated metastatic colorectal cancer.

Dr. Jain on the Need to Enroll Heterogenous Populations to Clinical Trials in CRC

December 14th 2021

Shikha Jain, MD, FACP, discusses the need to enroll heterogenous patient populations to clinical trials in colorectal cancer.

Dr. Azzi on the Utility of Signatera as a Preferred ctDNA Assay in CRC

December 8th 2021

Georges Azzi, MD, discusses the utility of the Signatera circulating tumor DNA assay as a preferred test in colorectal cancer (CRC).

Dr. Raghav on Treatment Considerations in Metastatic CRC

December 8th 2021

Kanwal Raghav, MBBS, MD, discusses treatment considerations in metastatic colorectal cancer.

Dr. Boland on Leveraging Triplet Chemo Regimens in Non-Resectable Liver-Only mCRC

December 7th 2021

Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.

Dr. Boland on Determining When to Utilize Up-front Perioperative Chemotherapy in CRC

December 6th 2021

Patrick Boland, MD, discusses determining when to utilize up-front perioperative chemotherapy for patients with colorectal cancer with liver metastases.

ESMO 2021 Updates in Gastric Cancer and Colorectal Cancer

December 6th 2021

Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.

Dr. Iqbal on Determining Whether to Start With Regorafenib or TAS-102 in mCRC

December 3rd 2021

Syma Iqbal, MD, discusses determining whether to start with regorafenib (Stivarga) or trifluridine/tipiracil (TAS-102; Lonsurf) in metastatic colorectal cancer (mCRC).

Dr. Raghav on Treatment Considerations With Regorafenib and TAS-102 in CRC

December 3rd 2021

Kanwal Raghav, MBBS, MD, discusses the safety profiles of regorafenib and trifluridine/tipiracil, and selecting between the agents for the treatment of patients with colorectal cancer.

Role of Genomic Testing in mCRC

November 30th 2021

Experts in gastrointestinal cancers review the role of genomic testing in metastatic colorectal cancer and its impact on informing treatment decisions.